KATP antagonists (glibenglamid) for use for promoting growth and/or treating hyperglycaemia of a premature infant
AssigneeAssistance Publique-Hopitaux de Paris
InventorsMichel Polak, Marianne Berdugo Polak
Life of this patent
Estimating the term…
Abstract
The present invention relates to pharmaceutical compositions comprising an ATP-sensitive potassium (K ATP) channel antagonist (e.g., sulfonylureas, meglitinides) and methods for treating hyperglycaemia and/or promoting growth of a premature and/or small for gestational age infant.
Claims15
A method for promoting growth in a preterm and/or small-for-gestational-age infant in need of growth promotion, comprising enterally administering a pharmaceutical composition comprising a therapeutically effective amount of a KATP channel antagonist selected from the group consisting of glibenclamide, acetohexamide, carbutamide, glibornuride, chlorpropamide, tolbutamide, tolazamide, glipizide, gliclazide, gliquidone, glyclopyramide, glisoxepide, glimepiride, repaglinide, nateglinide, mitiglinide and combinations thereof to the preterm and/or small-for-gestational-age infant, wherein the pharmaceutical composition is administered to the infant for a period of seven days to six months and the growth of said preterm and/or small-for-gestational-age infant is promoted.
Dependencies are inferred from the claim text.